Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2004-08-17 (21 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CAEN (14000), Calvados
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS GRANDE PHARMACIE DU PROGRES : revenue, balance sheet and financial ratios
SELAS GRANDE PHARMACIE DU PROGRES is a French company
founded 21 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CAEN (14000),
this company of category PME
shows in 2023 a revenue of 4.3 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS GRANDE PHARMACIE DU PROGRES (SIREN 478281561)
Indicator
2025
2024
2023
2020
2019
2017
2016
Revenue
N/C
N/C
4 312 026 €
N/C
N/C
N/C
N/C
Net income
264 553 €
182 645 €
132 047 €
197 657 €
251 966 €
267 097 €
311 774 €
EBITDA
N/C
N/C
198 000 €
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
3.1%
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELAS GRANDE PHARMACIE DU PROGRES generates positive net income of 265 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 312 k€ -> 265 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
264 553 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 130%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
130.493%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
34.253%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELAS GRANDE PHARMACIE DU PROGRES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2023
2024
2025
Debt ratio
123.871
102.484
653.729
424.729
182.528
159.358
130.493
Financial autonomy
36.634
41.486
10.635
15.638
29.216
30.995
34.253
Repayment capacity
None
None
None
None
15.937
None
None
Cash flow / Revenue
None%
None%
None%
None%
3.116%
None%
None%
Sector positioning
Debt ratio
130.492025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Average
In 2025, the debt ratio of SELAS GRANDE PHARMACIE DU... (130.49) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
34.25%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Average
In 2025, the financial autonomy of SELAS GRANDE PHARMACIE DU... (34.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
15.94 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Watch
In 2023, the repayment capacity of SELAS GRANDE PHARMACIE DU... (15.94) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 196.82. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
196.819
Liquidity indicators evolution SELAS GRANDE PHARMACIE DU PROGRES
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2019
2020
2023
2024
2025
Liquidity ratio
253.798
276.729
203.976
223.729
239.259
211.369
196.819
Interest coverage
None
None
None
None
12.896
None
None
Sector positioning
Liquidity ratio
196.822025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good-11 pts over 3 years
In 2025, the liquidity ratio of SELAS GRANDE PHARMACIE DU... (196.82) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
12.9x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Excellent
In 2023, the interest coverage of SELAS GRANDE PHARMACIE DU... (12.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELAS GRANDE PHARMACIE DU PROGRES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
1 272 651 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
95
0
0
Customer payment term (days)
80
0
0
0
10
0
0
Supplier payment term (days)
557
0
0
0
60
0
0
Positioning of SELAS GRANDE PHARMACIE DU PROGRES in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELAS GRANDE PHARMACIE DU PROGRES is estimated at
4 202 455 €
(range 2 851 806€ - 6 594 231€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
2851k€4202k€6594k€
4 202 455 €Range: 2 851 806€ - 6 594 231€
NAF 5 année 2025
Valuation method used
Net Income Multiple
264 553 €
×
15.9x
=4 202 456 €
Range: 2 851 806€ - 6 594 232€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS GRANDE PHARMACIE DU PROGRES with other companies in the same sector:
Frequently asked questions about SELAS GRANDE PHARMACIE DU PROGRES
What is the revenue of SELAS GRANDE PHARMACIE DU PROGRES ?
The revenue of SELAS GRANDE PHARMACIE DU PROGRES in 2023 is 4.3 M€.
Is SELAS GRANDE PHARMACIE DU PROGRES profitable?
Yes, SELAS GRANDE PHARMACIE DU PROGRES generated a net profit of 265 k€ in 2025.
Where is the headquarters of SELAS GRANDE PHARMACIE DU PROGRES ?
The headquarters of SELAS GRANDE PHARMACIE DU PROGRES is located in CAEN (14000), in the department Calvados.
Where to find the tax return of SELAS GRANDE PHARMACIE DU PROGRES ?
The tax return of SELAS GRANDE PHARMACIE DU PROGRES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS GRANDE PHARMACIE DU PROGRES operate?
SELAS GRANDE PHARMACIE DU PROGRES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart